The effects of intradermal botulinum toxin type a injections on pain symptoms of patients with diabetic neuropathy
Open Access
- 1 February 2014
- journal article
- research article
- Vol. 19 (2) , 106-111
Abstract
Background: Considering the dramatic increasing rate of diabetes and consequently its related complications, most importantly diabetic peripheral neuropathy (DPN), challenges regarding proper treatment of DPN and its effect on the quality-of-life and care of diabetic patients, the aim of this current study is to evaluate the effect of intradermal botulinum toxin type A (BTX-A) injections on pain symptoms of patients with diabetic neuropathic pain. Materials and Methods: In this randomized double-blind placebo-controlled clinical trial study, diabetic patients aged <70 years with neuropathic pain in both feet were enrolled. Diabetic neuropathy (DN) in selected patients was diagnosed using DN4 questionnaire and nerve conduction velocity examinations. They randomized in two intervention (BTX-A injection/100 unit, N = 20) and placebo groups (normal saline injection, N = 20). The outcome of injection on diabetic neuropathic pain was assessed using neuropathy pain scale (NPS) and visual analog scale (VAS) score and compared in two studied groups. Results: There was no significant difference in DN4, NPS and VAS scales of studied population after intervention in the placebo group. Intradermal injection of BTX-A reduced NPS scores for all items except cold sensation (P = 0.05). It reduced DN4 scores for electric shocks, burning, pins and needles and brushing (P < 0.05). According to VAS scale 30% and 0% of patients in intervention and placebo groups have no pain after intervention (P = 0.01). Conclusion: Intradermal injection of BTX-A is a well-tolerated agent that has a significant effect on DPN pain.Keywords
This publication has 24 references indexed in Scilit:
- Recent advances in the management of diabetic distal symmetrical polyneuropathyJournal of Diabetes Investigation, 2011
- Recent advances in pharmacological treatment of neuropathic painF1000 Medicine Reports, 2010
- Botulinum toxin type A reduces pain supersensitivity in experimental diabetic neuropathy: Bilateral effect after unilateral injectionEuropean Journal of Pharmacology, 2010
- 5% lidocaine medicated plaster versus pregabalin in post-herpetic neuralgia and diabetic polyneuropathy: an open-label, non-inferiority two-stage RCT studyCurrent Medical Research and Opinion, 2009
- Botulinum toxin for diabetic neuropathic painNeurology, 2009
- Neue Behandlungsmöglichkeit bei diabetischer GastropareseMedizinische Klinik, 2008
- Mechanisms of Disease: neuropathic pain—a clinical perspectiveNature Clinical Practice Neurology, 2006
- The Validity of the Neuropathic Pain Scale for Assessing Diabetic Neuropathic Pain in a Clinical TrialThe Clinical Journal of Pain, 2006
- Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4)Pain, 2005
- A Focused Review on the Use of Botulinum Toxins for Neuropathic PainThe Clinical Journal of Pain, 2002